Adavosertib can increase the chemotherapeutic drug sensitivity of cancer cells harbouring TP53 mutations (18, 19), and it was reported that in patients with platinum-sensitive ovarian cancer, adavosertib combined with paclitaxel and carboplatin can improve progression-free survival (PFS). Here, TP53 is linked to cancer.